Direkt zum Inhalt
Merck

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

A3480

Atosiban

≥98% (HPLC), oxytocin receptor antagonist, lyophilized powder

Synonym(e):

1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin, 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin, Tractocile

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
10 mg

Ab HEUTE lieferbarvonSchnelldorf

336,00 €

Über diesen Artikel

Empirische Formel (Hill-System):
C43H67N11O12S2
CAS-Nummer:
90779-69-4
Molekulargewicht:
994.19
UNSPSC Code:
51111800
PubChem Substance ID:
24724390
NACRES:
NA.77
MDL number:
MFCD00672436
Assay:
≥98% (HPLC)
Form:
lyophilized powder
Quality level:
100
Storage condition:
desiccated

336,00 €

Ab HEUTE lieferbarDetails

​
Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Atosiban, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

lyophilized powder

storage condition

desiccated

color

white

solubility

H2O: ≤100 mg/mL

originator

Ferring

shipped in

wet ice

storage temp.

−20°C

SMILES string

[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](Cc2ccc(OCC)cc2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O

InChI

1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1

InChI key

VWXRQYYUEIYXCZ-OBIMUBPZSA-N

Gene Information

human ... AVPR1A(552), OXTR(5021)
rat ... Oxtr(25342)

Application

Atosiban has been used:
  • as an oxytocin receptor antagonist
  • in the calcium mobilization assay for Z factor determination in uterine myometrium (UT-myo cells) and as a therapeutic agent to inhibit preterm labor
  • to inhibit the activation of oxytocin-receptor-expressing neurons in the parabrachial nucleus of mice (OxtrPBN)

Biochem/physiol Actions

Atosiban is a peptide oxytocin receptor antagonist.
Atosiban efficiently prevent preterm uterine contractions without any major cardiovascular, pulmonary or central nervous system side effects. It has potential to treat preterm labour.

Features and Benefits

This compound was developed by Ferring. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Reconstitute in deionized water at not less than 100 μg/mL, which can then be diluted into aqueous vehicle of choice. Solutions may be stored at 2-8 °C for up to seven days. For extended storage, add a carrier protein of 0.1% human serum albumin or bovine serum albumin and freeze in working aliquots at −20 °C.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
SML0246SML0271SML1994
Atosiban ≥98% (HPLC)

Sigma-Aldrich

A3480

Atosiban

Tirofiban hydrochloride monohydrate ≥98% (HPLC)

Sigma-Aldrich

SML0246

Tirofiban hydrochloride monohydrate

VER-155008 ≥98% (HPLC)

Sigma-Aldrich

SML0271

VER-155008

BOP >97% (HPLC)

Sigma-Aldrich

SML1994

BOP

form

lyophilized powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

>97% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

H2O: ≤100 mg/mL

solubility

DMSO: >12 mg/mL at warmed to 60 °C

solubility

DMSO: >10 mg/mL

solubility

H2O: 2 mg/mL, clear (warmed)

storage condition

desiccated

storage condition

desiccated

storage condition

desiccated

storage condition

desiccated

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000500547
0000500547
0000191298
0000175443
0000157673

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue
Romero R, et al.
American Journal of Obstetrics and Gynecology, 182(5), 1173-1183 (2000)
David M Haas et al.
BMJ (Clinical research ed.), 345, e6226-e6226 (2012-10-11)
To determine the most effective tocolytic agent at delaying delivery. Systematic review and network meta-analysis. Cochrane Central Register of Controlled Trials, Medline, Medline In-Process, Embase, and CINAHL up to 17 February 2012. Randomised controlled trials of tocolytic therapy in women
Peter Husslein
Acta obstetricia et gynecologica Scandinavica, 81(7), 633-641 (2002-08-23)
The incidence of preterm birth has remained unchanged for the last few decades. This is due, in part, to the complex etiology of preterm labor, and the limited ability of tocolytic agents to prolong pregnancy as a result of limited
Alle zugehörigen Dokumente anzeigen

Global Trade Item Number

SKUGTIN
A3480-10MG04061833360958

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter